<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818282</url>
  </required_header>
  <id_info>
    <org_study_id>2019-GYN/OC-01</org_study_id>
    <nct_id>NCT03818282</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer</brief_title>
  <acronym>OC-01</acronym>
  <official_title>Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) in Combination With Carboplatin for First-line Chemotherapy of Ovarian Cancer: A Multicenter, Open-label, Single-arm Phase 2 Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary evaluation of the efficacy and safety of paclitaxel for injection (albumin-bound)
      in combination with carboplatin for first-line chemotherapy of ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free Survival</measure>
    <time_frame>2 year</time_frame>
    <description>PFS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel for injection (albumin-bound)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel for injection (albumin-bound)</intervention_name>
    <description>Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.</description>
    <arm_group_label>Paclitaxel for injection (albumin-bound)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 75 years;

          -  Histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary
             peritoneal cancer;

          -  Patients with stage IC-IV according to the International Federation of Obstetrics and
             Gynecology (FIGO) and who underwent an ideal tumor reduction procedure within 6 weeks
             prior to enrollment;

          -  Lesion is measurable according to RECIST 1.1 criteria or patient's CA125 is evaluable
             according to GCIG criteria;

          -  ECOG performance status of 0-2;

          -  Expected survival ≥ 3 months;

          -  Bone marrow function: Neutrophils ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90
             g/L;

          -  Hepatic and renal function: Serum creatinine ≤ 1.5×ULN; AST and ALT ≤ 1.5×ULN or ≤
             5×ULN in the presence of hepatic metastasis; Total bilirubin ≤ 1.5×ULN, or ≤ 2.5×ULN
             in patients with Gilbert's syndrome;

          -  Must agree to use effective contraception during the trial; Women of childbearing
             potential must have a negative serum or urine pregnancy test; Non-lactating patients.

        Exclusion Criteria:

          -  Ovarian low-grade malignant tumor patients;

          -  Patients who have received abdominal or pelvic radiotherapy;

          -  Patients with central nervous system disease or brain metastases;

          -  Other malignancies have occurred within the last 5 years, except for cervical
             carcinoma in situ, non-melanoma skin cancers that have been cured;

          -  Prior Grade ≥ 2 sensory or motor neuropathy;

          -  Uncontrolled serious medical conditions that, in the opinion of the investigator,
             would affect the ability of the subject to receive the study regimen, such as
             concomitant serious medical conditions, including severe heart disease,
             cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension,
             uncontrolled infection, active peptic ulcer, etc.;

          -  Known to be hypersensitive, highly sensitive, or intolerant to study-related
             medications or their excipients;

          -  Receive other study drug chemotherapy within 30 days of the first dose of
             chemotherapy;

          -  Patients not suitable for participation in this study judged by investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ding Ma, M.D.</last_name>
    <phone>02783663351</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danhui Weng, M.D.</last_name>
    <phone>02783663351</phone>
    <email>weng.dh@gmail.com</email>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

